|
1
|
Pavel M, Öberg K, Falconi M, Krenning EP,
Sundin A and Perren A: ESMO Guidelines Committee: Electronic
address: clinicalguidelines@esmo.org. Gastroenteropancreatic
neuroendocrine neoplasms: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 31:844–860.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gribble FM and Reimann F: Function and
mechanisms of enteroendocrine cells and gut hormones in metabolism.
Nat Rev Endocrinol. 15:226–237. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO Classification of Tumours Editorial Board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Busico A, Maisonneuve P, Prinzi N,
Pusceddu S, Centonze G, Garzone G, Pellegrinelli A, Giacomelli L,
Mangogna A, Paolino C, et al: Gastroenteropancreatic high-grade
neuroendocrine neoplasms: Histology and molecular analysis, two
sides of the same coin. Neuroendocrinology. 110:616–629.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Milione M, Maisonneuve P, Pellegrinelli A,
Grillo F, Albarello L, Spaggiari P, Vanoli A, Tagliabue G, Pisa E,
Messerini L, et al: Ki67 proliferative index of the neuroendocrine
component drives MANEC prognosis. Endocr Relat Cancer. 25:583–593.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tang LH, Untch BR, Reidy DL, O'Reilly E,
Dhall D, Jih L, Basturk O, Allen PJ and Klimstra DS:
Well-differentiated neuroendocrine tumors with a morphologically
apparent high-grade component: A pathway distinct from poorly
differentiated neuroendocrine carcinomas. Clin Cancer Res.
22:1011–1017. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sorbye H, Kong G and Grozinsky-Glasberg S:
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms
(WHO G3). Endocr Relat Cancer. 27:R67–R77. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pellat A and Coriat R: Well differentiated
grade 3 neuroendocrine tumors of the digestive tract: A narrative
review. J Clin Med. 9(1677)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Venizelos A, Elvebakken H, Perren A,
Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO,
Sundlöv A, Svensson J, et al: The molecular characteristics of
high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr
Relat Cancer. 29:1–14. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Scarpa A, Chang DK, Nones K, Corbo V,
Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, et
al: Whole-genome landscape of pancreatic neuroendocrine tumours.
Nature. 543:65–71. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mafficini A and Scarpa A: Genetics and
epigenetics of gastroenteropancreatic neuroendocrine neoplasms.
Endocr Relat Cancer. 26:R249–R266. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jin XF, Spöttl G, Maurer J, Nölting S and
Auernhammer CJ: Antitumoral activity of the MEK inhibitor
trametinib (TMT212) alone and in combination with the CDK4/6
inhibitor ribociclib (LEE011) in neuroendocrine tumor cells in
vitro. Cancers (Basel). 13(1485)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang ZJ, An K, Li R, Shen W, Bao MD, Tao
JH, Chen JN, Mei SW, Shen HY, Ma YB, et al: Analysis of 72 patients
with colorectal high-grade neuroendocrine neoplasms from three
chinese hospitals. World J Gastroenterol. 25:5197–5209.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Uccella S, La Rosa S, Metovic J, Marchiori
D, Scoazec JY, Volante M, Mete O and Papotti M: Genomics of
high-grade neuroendocrine neoplasms: Well-differentiated
neuroendocrine tumor with high-grade features (G3 NET) and
neuroendocrine carcinomas (NEC) of various anatomic sites. Endocr
Pathol. 32:192–210. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mitsuhashi K, Yamamoto I, Kurihara H,
Kanno S, Ito M, Igarashi H, Ishigami K, Sukawa Y, Tachibana M,
Takahashi H, et al: Analysis of the molecular features of rectal
carcinoid tumors to identify new biomarkers that predict biological
malignancy. Oncotarget. 6:22114–22125. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Park HY, Kwon MJ, Kang HS, Kim YJ, Kim NY,
Kim MJ, Min KW, Choi KC, Nam ES, Cho SJ, et al: Targeted
next-generation sequencing of well-differentiated rectal, gastric,
and appendiceal neuroendocrine tumors to identify potential
targets. Hum Pathol. 87:83–94. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hijioka S, Hosoda W, Matsuo K, Ueno M,
Furukawa M, Yoshitomi H, Kobayashi N, Ikeda M, Ito T, Nakamori S,
et al: Rb loss and KRAS mutation are predictors of the response to
platinum-based chemotherapy in pancreatic neuroendocrine neoplasm
with grade 3: A japanese multicenter pancreatic NEN-G3 study. Clin
Cancer Res. 23:4625–4632. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sorbye H, Baudin E and Perren A: The
problem of high-grade gastroenteropancreatic neuroendocrine
neoplasms. Endocrinol Metab Clin North Am. 47:683–698.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Patil M, Pabla N and Dong Z: Checkpoint
kinase 1 in DNA damage response and cell cycle regulation. Cell Mol
Life Sci. 70:4009–4021. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qiu Z, Oleinick NL and Zhang J: ATR/CHK1
inhibitors and cancer therapy. Radiother Oncol. 126:450–464.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hubackova S, Davidova E, Boukalova S,
Kovarova J, Bajzikova M, Coelho A, Terp MG, Ditzel HJ, Rohlena J
and Neuzil J: Replication and ribosomal stress induced by targeting
pyrimidine synthesis and cellular checkpoints suppress
p53-deficient tumors. Cell Death Dis. 11(110)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jaaks P, Coker EA, Vis DJ, Edwards O,
Carpenter EF, Leto SM, Dwane L, Sassi F, Lightfoot H, Barthorpe S,
et al: Effective drug combinations in breast colon and pancreatic
cancer cells. Nature. 603:166–173. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pang YY, Chen ZY, Zeng DT, Li DM, Li Q,
Huang WY, Li B, Luo JY, Chi BT, Huang Q, et al: Checkpoint kinase 1
in colorectal cancer: Upregulation of expression and promotion of
cell proliferation. World J Clin Oncol. 16(101725)2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo
M, Wei R, Wang Y, Jurczyszyn A, Janz S, et al: CHEK1 and
circCHEK1_246aa evoke chromosomal instability and induce bone
lesion formation in multiple myeloma. Mol Cancer.
20(84)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q,
Guo Z, Liu L and Wu D: UBE2T-regulated H2AX monoubiquitination
induces hepatocellular carcinoma radioresistance by facilitating
CHK1 activation. J Exp Clin Cancer Res. 39(222)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zuo W, Zhang W, Xu F, Zhou J and Bai W:
Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to
regulate the chemotherapy sensitivity of lung adenocarcinoma cells
to cisplatin by regulating CHEK1. Cancer Cell Int.
19(240)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sen T, Tong P, Stewart CA, Cristea S,
Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, et al:
CHK1 inhibition in small-cell lung cancer produces single-agent
activity in biomarker-defined disease subsets and combination
activity with cisplatin or olaparib. Cancer Res. 77:3870–3884.
2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Booth L, Roberts J, Poklepovic A and Dent
P: The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to
kill carcinoma cells. Cancer Biol Ther. 19:786–796. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cui Q, Cai CY, Wang JQ, Zhang S, Gupta P,
Ji N, Yang Y, Dong X, Yang DH and Chen ZS: Chk1 inhibitor MK-8776
restores the sensitivity of chemotherapeutics in P-glycoprotein
overexpressing cancer cells. Int J Mol Sci. 20(4095)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Landau HJ, McNeely SC, Nair JS, Comenzo
RL, Asai T, Friedman H, Jhanwar SC, Nimer SD and Schwartz GK: The
checkpoint kinase inhibitor AZD7762 potentiates
chemotherapy-induced apoptosis of p53-mutated multiple myeloma
cells. Mol Cancer Ther. 11:1781–1788. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dai Y, Rahmani M, Pei XY, Khanna P, Han
SI, Mitchell C, Dent P and Grant S: Farnesyltransferase inhibitors
interact synergistically with the Chk1 inhibitor UCN-01 to induce
apoptosis in human leukemia cells through interruption of both Akt
and MEK/ERK pathways and activation of SEK1/JNK. Blood.
105:1706–1716. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Soldevilla B, Lens-Pardo A,
Espinosa-Olarte P, Carretero-Puche C, Molina-Pinelo S, Robles C,
Benavent M, Gomez-Izquierdo L, Fierro-Fernández M, Morales-Burgo P,
et al: MicroRNA signature and integrative omics analyses define
prognostic clusters and key pathways driving prognosis in patients
with neuroendocrine neoplasms. Mol Oncol. 17:582–597.
2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Li N, Hu Y, Wu L and An J:
Clinicopathological correlations in 38 cases of
gastroenteropancreatic high-grade neuroendocrine neoplasms. Front
Oncol. 14(1399079)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rosery V, Reis H, Savvatakis K, Kowall B,
Stuschke M, Paul A, Dechêne A, Yang J, Zhao B, Borgers A, et al:
Antitumor immune response is associated with favorable survival in
GEP-NEN G3. Endocr Relat Cancer. 28:683–693. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Konukiewitz B, Schlitter AM, Jesinghaus M,
Pfister D, Steiger K, Segler A, Agaimy A, Sipos B, Zamboni G,
Weichert W, et al: Somatostatin receptor expression related to TP53
and RB1 alterations in pancreatic and extrapancreatic
neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol.
30:587–598. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bellizzi AM: Immunohistochemistry in the
diagnosis and classification of neuroendocrine neoplasms: What can
brown do for you? Hum Pathol. 96:8–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Czeczok TW, Stashek KM, Maxwell JE,
O'Dorisio TM, Howe JR, Hornick JL and Bellizzi AM: Clusterin in
neuroendocrine epithelial neoplasms: Absence of expression in a
well-differentiated tumor suggests a jejunoileal origin. Appl
Immunohistochem Mol Morphol. 26:94–100. 2018.PubMed/NCBI View Article : Google Scholar
|
![Overall analysis of the DEGs. (A)
Volcano plot of the DEGs. Red and blue dots represent significantly
upregulated and downregulated genes, respectively (adjusted P-value
<0.05 and |log2FC|>1). (B) GO and KEGG enrichment
analysis of the DEGs. Bar plots show the top significantly enriched
terms. The x-axis represents the enrichment significance
[-Log10(adjusted P-value)], and numbers in parentheses
indicate gene counts for each term. DEGs, differentially expressed
genes; BP, biological processes; CC, cellular component; MF,
molecular function; KEGG, Kyoto Encyclopedia of Genes and
Genomes.](/article_images/etm/31/1/etm-31-01-13001-g01.jpg)
![Prognostic and diagnostic analysis of
the DEGs identified from the GSE211485 dataset. (A-E) Kaplan-Meier
survival curves showing the association between the expression
levels of the five identified DEGs (A) CHEK1, (B)
CENPF, (C) E2F7, (D) ITGB3BP and (E)
UBE2T, and overall survival in patients with digestive
system tumours. The HR and 95% CIs were calculated using the
log-rank test. (F) ROC curve showing the diagnostic performance of
CHEK1 expression for distinguishing tumour from normal
tissues. The AUC indicates diagnostic accuracy. (G) Expression of
CHEK1 [log2 (TPM +1)] in digestive system tumour tissues
compared with adjacent normal tissues. Statistical significance is
indicated as ***P<0.001. DEGs, differentially
expressed genes; CI, confidence interval; AUC, area under the
curve; HR, hazard ratio; CHEK1, checkpoint kinase 1; FPR,
false-positive rate; TPR, true-positive rate; TPM, transcripts per
million.](/article_images/etm/31/1/etm-31-01-13001-g03.jpg)
